恩扎卢胺联合亮丙瑞林治疗高危生化复发前列腺癌:EMBARK试验次要终点
EMBARK是一项全球多中心随机对照3期试验,纳入高危生化复发前列腺癌患者,按1:1:1随机分配至恩扎卢胺联合亮丙瑞林、亮丙瑞林单药或恩扎卢胺单药治疗。本文报告恩扎卢胺联合亮丙瑞林对比亮丙瑞林单药的次要疗效终点,联合治疗在无远处转移、无去势抵抗、无有症状进展等方面5年概率更高,但激素治疗相关症状的确认临床意义恶化时间以亮丙瑞林单药更优,中位差异很小(0.03个月)。
要点
- 联合治疗5年无远处转移概率91.0%,亮丙瑞林单药为81.5%。
- 联合治疗5年无去势抵抗概率96.6%,亮丙瑞林单药为67.8%。
- 激素相关症状恶化时间亮丙瑞林单药更优,但中位差异仅0.03个月。
核心结论
- 恩扎卢胺联合亮丙瑞林对比亮丙瑞林单药在多项次要疗效终点上显示获益,结合主要结果支持其作为高危生化复发前列腺癌的新标准治疗。
研究设计与样本
- EMBARK为全球多中心、随机、对照、3期试验,患者按1:1:1随机分配至恩扎卢胺联合亮丙瑞林、亮丙瑞林单药或恩扎卢胺单药。
- 本文报告非关键次要终点,包括至远处转移时间、重启任何激素治疗、去势抵抗、有症状进展和首次有症状骨骼事件。
- 激素治疗相关症状采用生活质量问卷前列腺25(QLQ-PR25)评估,时间事件终点用Kaplan-Meier法汇总并给出名义P值。
主要发现
- 恩扎卢胺联合亮丙瑞林对比亮丙瑞林单药的5年无远处转移概率为91.0%(95%CI 87.1-93.7) vs 81.5%(95%CI 76.3-85.7)。
- 5年未重启任何激素治疗概率为14.9%(95%CI 10.8-19.6) vs 7.8%(95%CI 4.4-12.3),5年无去势抵抗概率为96.6%(95%CI 93.9-98.1) vs 67.8%(95%CI 62.4-72.6)。
- 5年无有症状进展概率为70.9%(95%CI 65.5-75.6) vs 53.3%(95%CI 47.6-58.6),5年无首次有症状骨骼事件概率为97.8%(95%CI 95.4-98.9) vs 91.5%(95%CI 87.8-94.1)。
- 激素治疗相关症状确认临床意义恶化的时间以亮丙瑞林单药更优,中位差异很小(0.03个月)。
关键数值与推荐
- 5年无远处转移概率:恩扎卢胺联合亮丙瑞林91.0%(95%CI 87.1-93.7),亮丙瑞林单药81.5%(95%CI 76.3-85.7)。
- 5年未重启任何激素治疗概率:14.9%(95%CI 10.8-19.6) vs 7.8%(95%CI 4.4-12.3)。
- 5年无去势抵抗概率:96.6%(95%CI 93.9-98.1) vs 67.8%(95%CI 62.4-72.6)。
- 5年无有症状进展概率:70.9%(95%CI 65.5-75.6) vs 53.3%(95%CI 47.6-58.6);5年无首次有症状骨骼事件概率:97.8%(95%CI 95.4-98.9) vs 91.5%(95%CI 87.8-94.1)。
临床怎么用
- 对高危生化复发前列腺癌患者,可考虑恩扎卢胺联合亮丙瑞林以改善远处转移、去势抵抗及有症状进展等结局。
- 联合治疗在激素治疗相关症状恶化方面略逊于亮丙瑞林单药,但中位差异仅0.03个月,临床决策需综合获益与症状负担。
- 试验注册号为NCT02319837,可据此检索完整方案与主要终点结果。
局限性
- 本文报告的是非关键次要终点,采用名义P值,未提供预设的统计效能控制说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The primary analysis of EMBARK reported improved metastasis-free survival for enzalutamide plus leuprolide (enzalutamide combination) vs leuprolide plus placebo (leuprolide alone) in patients with high-risk biochemical recurrence while maintaining quality of life. Here, we present secondary efficacy end points for enzalutamide combination vs leuprolide alone. MATERIALS AND METHODS: EMBARK is a global, multicenter, randomized, controlled, phase 3 trial. Patients were randomized (1:1:1) to enzalutamide combination, leuprolide alone, or enzalutamide monotherapy. Non-key secondary end points reported herein include time to distant metastasis, resumption of any hormonal therapy, castration resistance, symptomatic progression, and first symptomatic skeletal event. Hormonal treatment-related symptoms were assessed using the Quality-of-Life Questionnaire-Prostate 25. Time-to-event end points were summarized using the Kaplan-Meier method, with nominal P values. RESULTS: Enzalutamide combination vs leuprolide alone was associated with increased 5-year probabilities (95% CI) for remaining free of distant metastasis (91.0% [87.1-93.7] vs 81.5% [76.3-85.7]), resumption of any hormonal therapy after treatment suspension (14.9% [10.8-19.6] vs 7.8% [4.4-12.3]), castration resistance (96.6% [93.9-98.1] vs 67.8% [62.4-72.6]), symptomatic progression (70.9% [65.5-75.6] vs 53.3% [47.6-58.6]), and first symptomatic skeletal event (97.8% [95.4-98.9] vs 91.5% [87.8-94.1]). Time to confirmed clinically meaningful deterioration of hormonal treatment-related symptoms favored leuprolide alone vs enzalutamide combination, although the median difference was small (0.03 months). CONCLUSIONS: Combined with the primary findings from EMBARK, data from non-key secondary efficacy end points strengthen support for enzalutamide combination as a new standard of care for patients with high-risk biochemical recurrence. CLINICAL TRIAL REGISTRATION NUMBER: NCT02319837.
引用
- Shore ND, Gleave M, De Giorgi U, et al. Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial. J Urol. 2025. PMID: 41364813. doi:10.1097/JU.0000000000004890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。